Kim Leuthner, PharmD, FIDSA

An expert in infectious diseases reviews best practices for improving personalized medicine when treating complicated urinary tract infections and highlights the importance of antimicrobial stewardship.

Kim Leuthner, PharmD, FIDSA, comments on the effect of COVID-19 on the epidemiology of complicated UTIs, the use of antibiotics, and antimicrobial resistance.

An infectious disease clinical specialist shares treatment considerations for patients with complicated urinary tract infections, including for patients with comorbidities and older patients, and reviews antimicrobial therapies for multidrug-resistant UTIs.

Kim Leuthner, PharmD, FIDSA, provides insight on distinguishing between complicated and uncomplicated UTIs, and patients who are at high risk for developing complicated UTIs.